This finding suggests that obesity may diminish the effectiveness of ICI therapy, which primarily activates and targets CD8+ T cells.24 Conversely, it is unlikely that obesity would reduce the therapeutic efficacy in patients receiving conventional chemotherapy, such as cytotoxic anticancer agents. Here, CD8A is linked to obesity due to melanocortin 4 receptor deficiency.